vimarsana.com

Latest Breaking News On - Nyse hae - Page 1 : vimarsana.com

Haemonetics Co (NYSE:HAE) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC trimmed its stake in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 14.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 110,313 shares of the medical instruments supplier’s stock after selling 18,094 shares during […]

Haemonetics Co Expected to Post Q1 2025 Earnings of $0 94 Per Share (NYSE:HAE)

Haemonetics Co. (NYSE:HAE – Free Report) – Zacks Research lifted their Q1 2025 EPS estimates for shares of Haemonetics in a report issued on Thursday, March 28th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $0.94 per share for the quarter, up from their prior estimate of […]

Haemonetics (NYSE:HAE) Issues Earnings Results

Haemonetics (NYSE:HAE – Get Free Report) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.94 by $0.10, Briefing.com reports. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company had revenue of $336.20 million for […]

Haemonetics (NYSE:HAE) Shares Gap Up on Strong Earnings

Haemonetics Co. (NYSE:HAE – Get Free Report) gapped up prior to trading on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $77.11, but opened at $81.26. Haemonetics shares last traded at $78.45, with a volume of 398,865 shares. The medical instruments supplier reported $1.04 EPS for the […]

Haemonetics (NYSE:HAE) Issues FY24 Earnings Guidance

Haemonetics (NYSE:HAE – Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $3.90-4.00 for the period, compared to the consensus EPS estimate of $3.89. The company issued revenue guidance of ~$1.28-1.31 billion, compared to the consensus revenue estimate of $1.27 billion. Haemonetics also updated its FY 2024 guidance […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.